EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the result.
PPJ Enterprise (OTCMKTS:PPJE - Get Free Report) and Fulgent Genetics (NASDAQ: FLGT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation. Earnings and Valuation This table compares PPJ
Fulgent Genetics offers a fortress balance sheet, zero debt, and net assets near the current share price, providing downside protection. FLGT's diagnostics business is growing, with 15.4% revenue growth YTD and all segments contributing, notably BioPharma services up 72%. Management is highly aligned, owning 33% of shares, executing opportunistic buybacks, and prioritizing disciplined M&A for further growth.
SG Americas Securities LLC acquired a new position in Fulgent Genetics, Inc. (NASDAQ: FLGT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 19,167 shares of the company's stock, valued at approximately $433,000. SG Americas Securities LLC owned 0.06% of Fulgent Genetics
Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has
ERO, NU, KSS, FLGT and BODI have been added to the Zacks Rank #1 (Strong Buy) List on Jan.12, 2026.
Bullfrog AI (NASDAQ: BFRG - Get Free Report) and Fulgent Genetics (NASDAQ: FLGT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Profitability This table compares Bullfrog AI and
Careview Communications (OTCMKTS:CRVW - Get Free Report) and Fulgent Genetics (NASDAQ: FLGT - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Institutional and Insider Ownership 48.1% of Fulgent Genetics
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire.
